Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Pregabalin Phonophoresis and MET for Knee Osteoarthritis

NCT: NCT07598474 · RECRUITING

NCT IDNCT07598474
StatusRECRUITING
Start Date2026-01-01
Completion2026-07-19

Brief Summary

Knee osteoarthritis (OA) is a common condition causing pain, stiffness, and difficulty walking. Many patients with advanced (Grade III) knee OA also experience neuropathic pain - burning, tingling, or electric shock sensations - which is harder to treat with standard physiotherapy. Oral pregabalin works for neuropathic pain but causes side effects like dizziness and drowsiness. This study tests whether delivering pregabalin through the skin using ultrasound (phonophoresis), combined with calf muscle stretching (Muscle Energy Technique), can reduce nerve pain and improve walking better than ultrasound alone.

Frequently Asked Questions

What is Pregabalin Phonophoresis and MET for Knee Osteoarthritis?

Pregabalin Phonophoresis and MET for Knee Osteoarthritis is a clinical trial registered under NCT07598474. Current status: RECRUITING.

What is the status of NCT07598474?

The current status of NCT07598474 (Pregabalin Phonophoresis and MET for Knee Osteoarthritis) is: RECRUITING.

When did Pregabalin Phonophoresis and MET for Knee Osteoarthritis start?

Pregabalin Phonophoresis and MET for Knee Osteoarthritis started on 2026-01-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.